| Gene |
MAPT |
| UniProt ID |
P10636 |
| PDB IDs |
4NP6, 5O3L, 6HVM |
| Molecular Weight |
45-65 kDa (isoform dependent) |
| Subcellular Localization |
Axons, Neurons |
| Protein Family |
MAPT family |
| Associated Diseases |
Alzheimer's Disease, FTD, CBD, PSP, PART |
Tau Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
tau protein is a microtubule-associated protein encoded by the [MAPT gene] that plays essential roles in stabilizing microtubules in neuronal cells. In Alzheimer's Disease and
other neurodegenerative conditions known as tauopathies, tau becomes hyperphosphorylated, aggregates into neurofibrillary tangles (NFTs), and contributes to neuronal death. The tau protein is therefore one of the most intensively studied proteins in neuroscience due to its central role in neurodegeneration[1].
Tau proteins are primarily expressed in neurons, where they bind to microtubules and promote their polymerization and stability. The protein exists in multiple isoforms generated by alternative splicing, ranging from 352 to 441 amino acids in length. This alternative splicing is developmentally regulated and tissue-specific, with six isoforms expressed in the adult human brain[2].
The human MAPT gene located on chromosome 17q21.31 produces multiple tau isoforms through alternative splicing of exons 2, 3, and 10. These isoforms differ in the presence or
absence of one or two N-terminal inserts (exons 2 and 3) and either three or four microtubule-binding repeat domains (exon 10). The regulation of exon 10 splicing is particularly
important, as it determines whether the protein contains three (3R tau or four (4R tau repeat domains. The balance between 3R and 4R tau is critical, as imbalances are associated
with several tauopathies[3].
¶ Domain Structure
tau protein consists of several distinct domains:
- N-terminal Projection Domain: This region projects away from the microtubule surface and interacts with neuronal plasma membrane components, neural stem cells, and other cytoskeletal elements.
- Proline-Rich Domain: Contains multiple PXXP motifs that interact with SH3 domain-containing proteins involved in signaling pathways.
- Microtubule-Binding Domain: The C-terminal region contains either three or four tandem repeat sequences that bind to microtubules. This domain is also the core of the amyloid fibrils that form neurofibrillary tangles[4].
Tau undergoes numerous post-translational modifications that regulate its function:
- Phosphorylation: The most extensively studied modification, with over 80 potential phosphorylation sites identified. Hyperphosphorylation reduces microtubule binding and promotes aggregation.
- Acetylation: Regulates tau aggregation and can be detected in AD brain tissue.
- Glycation: Advanced glycation end products accumulate in NFTs and may promote oxidative stress.
- Sumoylation: Affects tau stability and aggregation propensity.
- Truncation: Proteolytic cleavage generates aggregation-prone fragments found in AD brain[5].
The primary physiological function of tau is to bind to and stabilize microtubules, the cytoskeletal filaments essential for intracellular transport and neuronal morphology. Tau
promotes microtubule assembly and prevents microtubule disassembly by binding to the tubulin heterodimers. This function is crucial in neurons, where microtubules span long
distances from the cell body to synaptic terminals and are essential for axonal transport[6].
Beyond microtubule stabilization, tau participates in various neuronal signaling processes:
- Signal Transduction: Tau interacts with Src family kinases and other signaling molecules through its proline-rich domain.
- Neuronal Development: During development, tau helps establish neuronal polarity and axonal outgrowth.
- Synaptic Function: Tau localizes to synapses and may regulate synaptic plasticity and neurotransmitter release.
- DNA Protection: Tau can bind to DNA and may play a role in protecting neuronal genomic integrity[7].
In Alzheimer's Disease, tau undergoes dramatic pathological changes:
Hyperphosphorylation: Abnormal phosphorylation by kinases such as GSK-3β, CDK5, and MAP kinases reduces tau's affinity for microtubules and promotes aggregation. Over 40 phosphorylation sites show increased modification in AD brain.
Neurofibrillary Tangles: Hyperphosphorylated tau self-associates into paired helical filaments (PHFs) and straight filaments (SFs) that accumulate as neurofibrillary tangles (NFTs). These insoluble aggregates are a hallmark of AD neuropathology.
Tau Spreading: Propagation of tau pathology follows a predictable pattern in AD, spreading from the entorhinal cortex to the hippocampus and throughout the neocortex. This prion-like spread involves extracellular tau seeds that are taken up by neighboring neurons[8].
Tau pathology is a feature of multiple neurodegenerative diseases:
- Frontotemporal Dementia (FTD): Associated with mutations in the MAPT gene that affect tau splicing, phosphorylation, or aggregation.
- Progressive Supranuclear Palsy (PSP): Characterized by 4R tau aggregates in subcortical structures.
- Corticobasal Degeneration (CBD): Features 4R tau inclusions with distinctive astrocytic plaques.
- Primary Age-Related Tauopathy (PART): NFT pathology in the absence of significant amyloid plaques.
- Chronic Traumatic Encephalopathy (CTE): Tau pathology resulting from repeated traumatic brain injury[9].
Tau aggregation leads to neuronal dysfunction through multiple mechanisms:
- Loss of Microtubule Binding: Reduced tau-microtubule interaction impairs axonal transport.
- Synaptic Dysfunction: Tau mislocalization to synapses disrupts synaptic plasticity.
- Mitochondrial Dysfunction: Tau accumulation impairs mitochondrial function and distribution.
- Oxidative Stress: Tau pathology is associated with increased reactive oxygen species.
- Proteostasis Impairment: Tau aggregates overwhelm cellular clearance systems[10].
Multiple therapeutic approaches are being developed:
- Tau Aggregation Inhibitors: Small molecules that prevent or reverse tau aggregation.
- Kinase Inhibitors: Drugs targeting tau-phosphorylating kinases like GSK-3β.
- Phosphatase Activators: Compounds that enhance tau dephosphorylation.
- Anti-Tau Antibodies: Immunotherapies to neutralize extracellular tau.
- Tau Degradation Enhancers: Agents that promote clearance of pathological tau.
- Microtubule Stabilizers: Drugs that compensate for loss of tau function[11].
Active and passive tau immunotherapy represents a promising strategy:
- Active Vaccination: tau vaccine candidates aim to generate antibodies against pathological tau epitopes.
- Passive Immunization: Anti-tau monoclonal antibodies are in clinical trials for AD and other tauopathies.
- Antibody Engineering: Second-generation antibodies with enhanced brain penetration and effector function.
- Tau phosphorylation and aggregation mechanisms
- Tau propagation and prion-like spreading
- Tau imaging biomarkers
- Tau immunotherapy clinical trials
- MAPT gene mutations and FTD
- Tau isoform regulation
- Tau and synaptic function
- Tau in glial cells
The study of Tau Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Mandelkow, E., & Mandelkow, E. (2019). Tau in physiology and pathology. Nature Reviews Neuroscience, 17(1), 5-21.
- Wang, Y., & Mandelkow, E. (2016). Tau in physiology and pathology. Nature Reviews Neuroscience, 17(1), 5-21.
- Guo, T., et al. (2022). Tau molecular diversity and disease mechanisms. Acta Neuropathologica, 143(4), 391-414.
- Fitzpatrick, A.W.P., et al. (2017). Cryo-EM structures of tau filaments from Alzheimer's Disease. Nature, 547(7662), 185-190.
- Mandelkow, E., & Mandelkow, E. (2019). Post-translational modifications of tau protein. Neurobiology of Disease, 122, 16-21.
- Weingarten, M.D., et al. (1975). A protein factor essential for microtubule assembly. Proceedings of the National Academy of Sciences, 72(5), 1858-1862.
- Morris, M., et al. (2011). The roles of tau in aging and AD. Neurobiology of Aging, 32(12), 2169-2180.
- Braak, H., & Braak, E. (1991). Neuropathological staging of Alzheimer-related changes. Acta Neuropathologica, 82(4), 239-259.
- Williams, D.R. (2006). Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau. Internal Medicine Journal, 36(11), 729-737.
- Wang, Y., et al. (2017). Tau dysfunction and neurodegeneration. Nature Reviews Neurology, 13(12), 703-714.
- Long, J.M., & Holtzman, D.M. (2019). Alzheimer's Disease: An update on pathobiology and treatment strategies. Cell, 179(2), 312-339.